188 related articles for article (PubMed ID: 23532886)
1. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
3. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
4. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
5. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
6. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
8. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
[TBL] [Abstract][Full Text] [Related]
11. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Goh KC; Novotny-Diermayr V; Hart S; Ong LC; Loh YK; Cheong A; Tan YC; Hu C; Jayaraman R; William AD; Sun ET; Dymock BW; Ong KH; Ethirajulu K; Burrows F; Wood JM
Leukemia; 2012 Feb; 26(2):236-43. PubMed ID: 21860433
[TBL] [Abstract][Full Text] [Related]
12. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
Le Rhun E; von Achenbach C; Lohmann B; Silginer M; Schneider H; Meetze K; Szabo E; Weller M
Int J Cancer; 2019 Jul; 145(1):242-253. PubMed ID: 30549269
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
McMillin DW; Delmore J; Negri J; Buon L; Jacobs HM; Laubach J; Jakubikova J; Ooi M; Hayden P; Schlossman R; Munshi NC; Lengauer C; Richardson PG; Anderson KC; Mitsiades CS
Br J Haematol; 2011 Feb; 152(4):420-32. PubMed ID: 21223249
[TBL] [Abstract][Full Text] [Related]
14. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.
Pallis M; Abdul-Aziz A; Burrows F; Seedhouse C; Grundy M; Russell N
Br J Haematol; 2012 Oct; 159(2):191-203. PubMed ID: 22934750
[TBL] [Abstract][Full Text] [Related]
15. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
17. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Feng R; Ma H; Hassig CA; Payne JE; Smith ND; Mapara MY; Hager JH; Lentzsch S
Mol Cancer Ther; 2008 Jun; 7(6):1494-505. PubMed ID: 18566220
[TBL] [Abstract][Full Text] [Related]
18. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of ERK5 targeting in triple negative breast cancer.
Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A
Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956
[TBL] [Abstract][Full Text] [Related]
20. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
